Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I
Recommended Citation
Rolle CP, D'Antoni ML, Corales R, Marongiu A, Gruber J, Schreibman T, Bell D, Hsiao CB, and Brar I. Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I. AIDS Res Ther 2025;22(1):126.
Document Type
Article
Publication Date
11-28-2025
Publication Title
AIDS research and therapy [electronic resource]
Keywords
Humans, HIV Infections, Adult, Retrospective Studies, Male, Female, Middle Aged, Anti-HIV Agents, Viremia, Viral Load, HIV-1, Tenofovir, Treatment Outcome, Emtricitabine, Adenine, Alanine, Drug Resistance, Viral, Amides, Heterocyclic Compounds, 3-Ring, Piperazines, Pyridones
Abstract
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is indicated for people with HIV who are virologically suppressed, including those with M184V/I. Data on B/F/TAF effectiveness during viremia with M184V/I are limited. This observational study retrospectively collected clinical/demographic data from adults with viremia and M184V/I receiving B/F/TAF or alternate antiretroviral therapy (ART). Virologic suppression at 3 and ≥ 6 months was evaluated. For participants with data, 5/5 (100%) and 7/8 (88%) on B/F/TAF and 4/6 (67%) and 7/10 (70%) on alternate ART achieved virologic suppression at 3 and ≥ 6 months, respectively. Virologic suppression was achieved in most people with HIV who were viremic with M184V/I on B/F/TAF, as with alternate ART.
Medical Subject Headings
Humans; HIV Infections; Adult; Retrospective Studies; Male; Female; Middle Aged; Anti-HIV Agents; Viremia; Viral Load; HIV-1; Tenofovir; Treatment Outcome; Emtricitabine; Adenine; Alanine; Drug Resistance, Viral; Amides; Heterocyclic Compounds, 3-Ring; Piperazines; Pyridones
PubMed ID
41316196
Volume
22
Issue
1
First Page
126
Last Page
126
